Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats

Experimental Eye Research

Volumn 89, Issue 5, 2009, Pages 686-692

  Klocek, Matthew S ^a   Sassani, Joseph W ^a   McLaughlin, Patricia J ^a   Zagon, Ian S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

cornea; diabetes; insulin; naltrexone; opioid antagonist; wound healing

Indexed keywords

GLUCOSE; INSULIN; MOXIFLOXACIN; NALTREXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA THICKNESS; DRUG EFFICACY; DRUG POTENTIATION; FLUORESCENCE ANALYSIS; GLUCOSE BLOOD LEVEL; IMAGE ANALYSIS; INSULIN DEPENDENT DIABETES MELLITUS; INTRAOCULAR PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; WOUND HEALING;

ADMINISTRATION, TOPICAL; ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DNA REPLICATION; DRUG THERAPY, COMBINATION; EPITHELIUM, CORNEAL; HYPOGLYCEMIC AGENTS; INSULIN; INTRAOCULAR PRESSURE; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; NECROSIS; OPHTHALMIC SOLUTIONS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; WOUND HEALING;

EID: 70349467860     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2009.06.010     Document Type: Article

References (25)

1. Ahren B., Stern J.S., Gingerich R.L., Curry D.L., and Havel P.J. Glucoagon secretory responses to hypoglycemia, adrenaline, and carbachol in streptozotocin diabetic rats. Acta Physiol. Scand. 155 (1995) 215-221
2. Cavallerano J. Ocular manifestations of diabetes mellitus. Optom. Clin. 2 (1992) 93-116
3. Waf1/Cip1 pathways to restrict normal cell proliferation. Mol. Biol. Cell 20 (2009) 319-327
4. Cisarnik-Fredenburg P. Discoveries in research on diabetic keratopathy. Optometry 72 (2001) 691-704
5. Crosson C.E., Klyce S.D., and Beuerman R.W. Epithelial wound closure in the rabbit. A biphasic process. Invest. Ophthalmol. Vis. Sci. 27 (1986) 464-473
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
7. Havel P.J., Hahn T.M., Sindelar D.K., Baskin D.G., Dallman M.F., Weigle D.S., and Schwartz M.W. Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 49 (2000) 244-252
8. Kabosova A., Kramerov A.A., Aoki A.M., Murphy G., Zieske J.D., and Ljubimov A.V. Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp. Eye Res. 77 (2003) 211-217
9. Kaji Y. Prevention of diabetic keratopathy. Br. J. Ophthalmol. 89 (2005) 254-255
10. Klocek M.S., Sassani J.W., McLaughlin P.J., and Zagon I.S. Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J. Ocul. Pharmacol. Ther. 23 (2007) 89-102
11. Nakahara M., Miyata K., Otani S., Miyai T., Nejima R., Yamagami S., and Amano S. A randomized, placebo-controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients. Br. J. Ophthalmol. 89 (2005) 226-268
12. Nakamura M., Sao N., Chikama T.I., Hasegawa Y., and Nishida T. Fibronectin facilitates corneal epithelial wound healing in diabetic rats. Exp. Eye Res. 64 (1997) 335-359
13. Pflugfelder S.C. Is autologous serum a tonic for the ailing corneal epithelium?. Am. J. Ophthalmol. 142 (2006) 316-317
14. Sanchez-Thorin J.C. The cornea in diabetes mellitus. Int. Ophthalmol. Clin. 38 (1998) 19-36
15. Schultz R.O., Van Horn D.L., Peters M.A., Klewin K.M., and Schutten W.H. Diabetic keratopathy. Trans. Am. Ophthalmol. Soc. 79 (1981) 180-189
16. Schulze S.D., Sekundo W., and Kroll P. Autologous serum for the treatment of corneal epithelial abrasions in diabetic patients undergoing vitrectomy. Am. J. Ophthalmol. 142 (2006) 207-211
17. Zagon I.S., Sassani J.W., and McLaughlin P.J. Re-epithelialization of the rabbit cornea is regulated by opioid growth factor. Brain Res. 803 (1998) 61-68
18. Zagon I.S., Sassani J.W., and McLaughlin P.J. Re-epithelialization of the rat cornea is accelerated by blockade of opioid receptors. Brain Res. 798 (1998) 254-260
19. Zagon I.S., Sassani J.W., and McLaughlin P.J. Re-epithelialization of the human cornea is regulated by endogenous opioids. Invest. Ophthalmol. Vis. Sci. 41 (2000) 73-81
20. Zagon I.S., Jenkins J.B., Sassani J.W., Wylile J.D., Ruth T.B., Frey J.L., Lang C.M., and McLaughlin P.J. Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes 51 (2002) 3055-3062
21. Zagon I.S., Verderame M.F., and McLaughlin P.J. The biology of the opioid growth factor receptor (OGFr). Brain Res. Rev. 38 (2002) 351-376
22. Zagon I.S., Sassani J.W., and McLaughlin P.J. Adaptations of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea 25 (2006) 821-829
23. Zagon I.S., Klocek M.S., Sassani J.W., and McLaughlin P.J. Corneal safety of topically applied naltrexone. J. Ocul. Pharmacol. Ther. 22 (2006) 377-387
24. Zagon I.S., Sassani J.W., and McLaughlin P.J. Insulin treatment ameliorates impaired corneal re-epithelialization in diabetic rats. Diabetes 85 (2006) 1141-1147
25. Zagon I.S., Klocek M.S., Sassani J.W., and McLaughlin P.J. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch. Ophthalmol. 125 (2007) 1082-1088